Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:COGTNASDAQ:DAWNNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.98-1.0%$2.48$1.95▼$4.98$198.81M1.23328,670 shs98,361 shsCOGTCogent Biosciences$6.48-2.0%$7.87$5.88▼$12.61$752.55M1.81.24 million shs1.85 million shsDAWNDay One Biopharmaceuticals$8.07-1.5%$10.60$7.88▼$18.07$817.94M-1.381.10 million shs598,146 shsREPLReplimune Group$10.39-0.6%$12.67$4.92▼$17.00$800.19M1.3858,281 shs368,583 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-5.71%-22.35%-27.47%-34.65%COGTCogent Biosciences0.00%-9.50%-7.30%-16.28%-0.61%DAWNDay One Biopharmaceuticals0.00%-1.94%-14.51%-37.30%-48.89%REPLReplimune Group0.00%-3.97%-17.80%-15.25%+25.94%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.4552 of 5 stars3.52.00.00.02.70.81.3COGTCogent Biosciences2.1626 of 5 stars4.41.00.00.02.10.00.6DAWNDay One Biopharmaceuticals2.921 of 5 stars4.62.00.00.01.92.50.0REPLReplimune Group3.7034 of 5 stars3.60.00.04.52.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00506.06% UpsideCOGTCogent Biosciences 2.75Moderate Buy$14.43122.66% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$32.29300.07% UpsideREPLReplimune Group 3.13Buy$19.4386.99% UpsideCurrent Analyst Ratings BreakdownLatest ACIU, REPL, COGT, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/7/2025COGTCogent BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025COGTCogent BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$17.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.002/27/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.002/26/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/26/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.002/26/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.002/26/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $36.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$27.31M7.28N/AN/A$2.12 per share0.93COGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/ADAWNDay One Biopharmaceuticals$131.16M6.24N/AN/A$3.98 per share2.03REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%5/12/2025 (Estimated)COGTCogent Biosciences-$192.41M-$1.94N/AN/AN/AN/A-112.55%-60.44%5/6/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$1.08N/AN/AN/AN/A-22.40%-19.79%5/5/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%5/15/2025 (Estimated)Latest ACIU, REPL, COGT, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 million2/12/2025Q3 2025REPLReplimune Group-$0.70-$0.79-$0.09-$0.79N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86COGTCogent BiosciencesN/A6.446.44DAWNDay One BiopharmaceuticalsN/A14.6214.55REPLReplimune Group0.1411.4311.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%COGTCogent BiosciencesN/ADAWNDay One Biopharmaceuticals87.95%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%COGTCogent Biosciences5.92%DAWNDay One Biopharmaceuticals8.40%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableCOGTCogent Biosciences80113.85 million103.92 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableREPLReplimune Group21077.02 million70.24 millionOptionableACIU, REPL, COGT, and DAWN HeadlinesRecent News About These Companies611,013 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by Artisan Partners Limited PartnershipMarch 30 at 4:59 AM | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National BankMarch 30 at 3:17 AM | marketbeat.comCharles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL)March 25, 2025 | marketbeat.comRosalind Advisors Inc. Purchases New Position in Replimune Group, Inc. (NASDAQ:REPL)March 23, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Down 5.6% - What's Next?March 22, 2025 | marketbeat.comVictory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL)March 22, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by BrokeragesMarch 17, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Up 6.4% - Still a Buy?March 13, 2025 | marketbeat.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comNew York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL)March 5, 2025 | marketbeat.comLos Angeles Capital Management LLC Lowers Position in Replimune Group, Inc. (NASDAQ:REPL)March 4, 2025 | marketbeat.comReplimune price target raised to $18 from $16 at JPMorganFebruary 26, 2025 | markets.businessinsider.comReplimune price target raised to $22 from $21 at H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comNavigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global RisksFebruary 13, 2025 | msn.comReplimune stock target raised to $22 at H.C. WainwrightFebruary 13, 2025 | msn.comBarclays Keeps Their Buy Rating on Replimune Group (REPL)February 13, 2025 | markets.businessinsider.comReplimune price target raised to $19 from $16 at WedbushFebruary 12, 2025 | markets.businessinsider.comReplimune price target raised to $21 from $18 at LeerinkFebruary 12, 2025 | markets.businessinsider.comReplimune: A Misunderstood Contender In OncolyticsFebruary 12, 2025 | seekingalpha.comReplimune reports Q3 EPS (79c) vs (77c) last yearFebruary 12, 2025 | markets.businessinsider.comReplimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate UpdateFebruary 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACIU, REPL, COGT, and DAWN Company DescriptionsAC Immune NASDAQ:ACIU$1.98 -0.02 (-1.00%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.92 -0.06 (-3.03%) As of 03/28/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Cogent Biosciences NASDAQ:COGT$6.48 -0.13 (-1.97%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$6.48 +0.00 (+0.08%) As of 03/28/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Day One Biopharmaceuticals NASDAQ:DAWN$8.07 -0.12 (-1.47%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.07 0.00 (0.00%) As of 03/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Replimune Group NASDAQ:REPL$10.39 -0.06 (-0.57%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$10.39 0.00 (0.00%) As of 03/28/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
